<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119924</url>
  </required_header>
  <id_info>
    <org_study_id>IRB098-33</org_study_id>
    <nct_id>NCT01119924</nct_id>
  </id_info>
  <brief_title>A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain</brief_title>
  <official_title>Phase IV Study for Evaluation the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nang Kuang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nang Kuang Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Efficacy and Safety of Smilon® in the Depression
      Patients with pain. Eligible patients will be randomly assigned to 1 of 2 arms, either
      Smilon® or placebo, and will receive the treatment for 8 weeks in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of pain intensity using the visual analog scale (VAS)</measure>
    <time_frame>8-week treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Severity of depressive symptom using the Depression and Somatic Symptoms Scale (DSSS)</measure>
    <time_frame>8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Severity of depressive and anxious symptom using the Hamilton depression scale (HAM-D) and Hamilton anxiety scale (HAM-A)</measure>
    <time_frame>8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life assessed by a 28-item WHOQoL self-administered questionnaire</measure>
    <time_frame>8-week treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Depression</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Mirtazapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mirtazapine 15mg/day or placebo once a day on the fist week, then 30 mg/day or placebo once a day, and then for 7 consecutive weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Smilon®</intervention_name>
    <description>Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks</description>
    <arm_group_label>Mirtazapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age 20-65 years

          -  Diagnosis of at least one chronic pain syndrome and the diagnosis of concomitant
             depression according to DSM-IV criteria

          -  Have a mean weekly pain score of at least 30 mm on the 100-mm visual analog scale
             (VAS) of the Short-Form McGill Pain Questionnaire (SF-MPQ) before study entry

        Exclusion Criteria:

          -  Women of child bearing potential who are pregnant, breastfeeding or not using
             effective contraceptives

          -  Known hypersensitivity to Mirtazapine or any of its components

          -  Subjects who have a clinically significant or unstable medical or psychiatric
             condition

          -  Subjects who have received nerve blocks or acupuncture for pain relief
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsai Hsin Chi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospitsl</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nang Kuang Pharmaceutical Co., LTD</name>
      <address>
        <city>Tainan</city>
        <state>Xinhua Township</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hsu Cindy</name_title>
    <organization>Nang Kuang Pharmaceutical Co., LTD</organization>
  </responsible_party>
  <keyword>Mirtazapine</keyword>
  <keyword>Smilon</keyword>
  <keyword>Depression</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

